ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Freireich Blasts Prevention Advocates, Defends Treatment

September 15, 1978

In Brief: Construction Grant Applications Due Oct. 1 For Funding In FY 1982; Backlog Cleared Out

June 19, 1981

825,000 Pounds of Yew Bark Clleced in ’91 For 10,000 Patients

March 13, 1992

National Toxicology Program: Saccharin No Longer Listed as Carcinogen in NTP Report

May 19, 2000

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

NCCS Networker Volume 6 Issue 1, Winter 1992

January 13, 1992